Kyverna Therapeutics, Inc. KYTX
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- -53.51%
- 1 year
- -46.90%
5D -0.48 (-9.47%)
- Market cap
- 276.28M
- EPS (ttm)
- -2.75
- Shares out
- 43.17M
- Forward P/E
- -1.00
- YTD return
- -53.51%
- 1-year return
- -46.90%
- 50-day average
- 4.93
- 200-day average
- 10.72
- Volume
- 823.76K
- Avg volume
- 858.76K
- Open
- 4.47
- Previous close
- 4.48
- Day's range
- 4.30 – 4.62
- 52-week range
- 4.30 – 13.67
- Analysts
- Buy
- Price target
- 27.33 (+525.5%)
Key statistics
- Enterprise value
- -139.78M
- Price / book
- 0.56
- Free cash flow
- -63.37M
- Total cash
- 321.59M
- Total debt
- 9.14M
- Return on equity
- -59.58%
- Short % of float
- 6.34%
Fundamental scorecard
4 of 25 checks passed on KYTX’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.77 | -0.80 | -0.03 | -3.90% |
| Aug 12, 2024 | Jun 1, 2024 | -0.70 | — | — | — |
| Aug 12, 2024 | Jun 1, 2024 | -0.70 | -0.67 | +0.03 | +4.29% |
| May 14, 2024 | Mar 1, 2024 | -0.88 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.88 | -1.12 | -0.24 | -27.27% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 20, 2024 | HC Wainwright & Co. | main | Neutral | Neutral |
| Nov 15, 2024 | Wells Fargo | main | Overweight | Overweight |
| Oct 10, 2024 | UBS | init | — | Buy |
| Sep 19, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Aug 15, 2024 | HC Wainwright & Co. | main | Neutral | Neutral |
| Jul 31, 2024 | JP Morgan | main | Overweight | Overweight |
About Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kyvernatx.com
News
Red Cat Downbeat Q3 Results, Joins Omeros, Deutsche Bank And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Did Kyverna Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Kyverna Therapeutics Q3 EPS $(0.68) Beats $(0.69) Estimate
Kyverna Therapeutics Completes BLA Submission For Miv-Cel In SPS Completed With Request For Priority Review; Says KYSA-6 Phase 3 gMG Trial Enrollment On-Track For Completion In Mid-2027
Kyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial Results Kyverna Therapeutics Publishes Primary Analysis Of KYSA-8 Trial In Participants With Stiff Person Syndrome In Journal Of American Medical Association Neurology
12 Health Care Stocks Moving In Friday's Pre-Market Session Kyverna Therapeutics Presents Updated Results From Its Phase 1 Trial Of CD-19 Directed CAR T-Cell Therapy In Progressive Multiple Sclerosis At MS Toronto 2026
Kyverna Therapeutics To Present Full One-Year Data Set From KYSA-8, Registrational Trial Of Miv-Cel In Patients With Stiff Person Syndrome, At MS Toronto 2026, Joint ACTRIMS-ECTRIMS Meeting
Your note
Sign in to keep a note on KYTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAIN CAPITAL LIFE SCIENCES INVESTORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 11, 2024 | 0 |
| COHEN FREDERICK E. M.D. PH.D. | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 11, 2024 | 0 |
| GILEAD SCIENCES INC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 11, 2024 | 4,126,120 |
| JONES RYAN ALEXANDER | Chief Financial Officer | Conversion of Exercise of derivative security | May 27, 2024 | 43,950 |
| NORTHPOND VENTURES III GP, L.L.C. | Former | Purchase | Feb 11, 2024 | 0 |
| SEIDENBERG BETH C | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 11, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vida Ventures Advisors, LLC | 10.48% | 4,523,924 | 17.73M | Sep 29, 2024 |
| Bain Capital Life Sciences Investors, LLC | 7.80% | 3,368,370 | 13.20M | Sep 29, 2024 |
| Northpond Ventures, Llc | 7.54% | 3,255,426 | 12.76M | Sep 29, 2024 |
| JP Morgan Chase & Company | 5.53% | 2,387,352 | 9.36M | Sep 29, 2024 |
| Novo Holdings A/S | 4.29% | 1,850,000 | 7.25M | Sep 29, 2024 |
| Blackrock Inc. | 3.52% | 1,520,261 | 5.96M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| JP Morgan Small Cap Growth Fund | 2.39% | 1,031,546 | 4.04M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 1.47% | 633,844 | 2.48M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.05% | 451,759 | 1.77M | Oct 30, 2024 |
| Franklin Strategic Series-Franklin Biotechnology Discove | 0.57% | 244,900 | 960.01K | Jul 30, 2024 |
| Vanguard Extended Market Index Fund | 0.54% | 232,962 | 913.21K | Sep 29, 2024 |
| Franklin Strategic Series-Franklin Small Cap Growth Fund | 0.52% | 224,100 | 878.47K | Jul 30, 2024 |
